Physician profile
Sarah Wall
NPI 1174815708
$33,439.97
in general payments reported to CMS, 2019-2025
16 companies · $3,958 in 2025
The $3,958 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $4,714 · 2023: $6,739 · 2024: $18K · 2025: $3,958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $6,600 · Honoraria: $3,695 · Consulting Fee: $1,740 · Travel and Lodging: $1,464 · Food and Beverage: $1,296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,930.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $6,600.00 |
| Honoraria | $3,695.00 |
| Consulting Fee | $1,740.00 |
| Travel and Lodging | $1,464.45 |
| Food and Beverage | $1,296.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $14,242.71 | 2024 | |
| Cti Biopharma Corp. | $6,681.15 | 2023 | Vonjo |
| Autolus INC | $3,337.87 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $2,768.00 | 2022 | |
| National Marrow Donor Program | $2,388.46 | 2024-2025 | |
| Celgene Corporation | $1,803.84 | 2022 | |
| Morphosys, US INC. | $1,797.92 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $253.28 | 2022-2024 | |
| Medexus Pharma, INC. | $83.63 | 2025 | Grafapex |
| Iovance Biotherapeutics, INC. | $47.54 | 2024 | Amtagvi |
| Johnson & Johnson Surgical Vision, INC. | $23.32 | 2024 | Tecnis Iol |
| Pharmaessentia USA Corporation | $12.25 | 2022 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Wall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.